Massimo Breccia | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Young CML Patients Treated Frontline with Imatinib or Second Generation TKIs: Clinical Characteristics and Outcome	BLOOD	2016
Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment	BLOOD	2016
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome	ONCOTARGET	2016
Cutaneous Lesions Anticipating Accelerated Phase of Multidrug Resistant Chronic Myeloid Leukemia Responsive to Ponatinib	MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES	2016
AZACITIDINE IN THE TREATMENT OF PH- MYELOPROLIFERATIVE NEOPLASMS IN BLASTIC PHASE: THE EXPERIENCE OF GRUPPO LAZIALE FOR THE STUDY OF PH- SMPC	HAEMATOLOGICA	2016
Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia	EXPERT OPINION ON DRUG SAFETY	2016
Peripheral Blood Flow-Cytometry Chronic Myeloid Leukemia Stem Cells Detection and Quantification during Tyrosine Kinase Inhibitors Therapy	BLOOD	2016
Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia	NEOPLASIA	2016
Early molecular response in chronic myeloid leukemia and halving time: Latest evidences	LEUKEMIA RESEARCH	2016
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia	AMERICAN JOURNAL OF HEMATOLOGY	2016
Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy	BLOOD	2016
IS A 1ST LINE ERYTHROPOIETIN APPROACH IN MYELODYSPLASTIC PATIENTS WITH DEL 5Q-USEFUL?	HAEMATOLOGICA	2016
A PROSPECTIVE EVALUATION OF THE IMPACT OF TRANSFUSION DEPENDENCY ON QUALITY OF LIFE AND SYMPTOM BURDEN IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES	HAEMATOLOGICA	2016
Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase	HAEMATOLOGICA	2016
PREDICTORS FOR RESPONSE TO RUXOLITINIB IN REAL-LIFE: AN OBSERVATIONAL INDEPENDENT STUDY ON 266 PATIENTS WITH MYELOFIBROSIS	HAEMATOLOGICA	2016
Obesity As a Risk Factor for Acute Promyelocytic Leukemia. Results from Population and Case-Control Studies Across Western Countries and Correlation with Gene Expression in the TCGA	BLOOD	2016
HOW PATIENTS PERCEIVE A SWITCH FROM IMATINIB TO NILOTINIB: RESULTS OF A PATIENT-CENTERED ANALYSIS	HAEMATOLOGICA	2016
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis	BLOOD	2016
PML-RAR alpha kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy	LEUKEMIA	2016
HOME CARE ADMINISTRATION OF SUBCUTANEOUS AZACITIDINE (AZA) AND DOMICILIARY MANAGEMENT OF FRAIL PATIENTS AFFECTED BY ACUTE MYELOID LEUKEMIA/MYELODYSPLASTIC SYNDROME: A FEASIBILITY STUDY	HAEMATOLOGICA	2016